1-((5-bromopentyl)oxy)-4-(tert-butyl)benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-((5-bromopentyl)oxy)-4-(tert-butyl)benzene
• 英文别名: 1-[(5-Bromopentyl)oxy]-4-tert-butylbenzene；1-(5-bromopentoxy)-4-tert-butylbenzene
• 化学式: C₁₅H₂₃BrO
• 分子量: 299.251
• InChiKey: YIYDSZRQIKKMQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  茚 、 1-((5-bromopentyl)oxy)-4-(tert-butyl)benzene 在 正丁基锂 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 15.0h， 以80%的产率得到3-[5-(4-tert-butylphenoxy)pentyl]-1H-indene
  参考文献：
  名称：

  ω-Phenoxyalkyl substituted bis(indenyl)zirconium dichloride complexes as catalysts for homogeneous ethylene polymerization

  摘要：

  Nine bis(indenyl) zirconium dichloride complexes of the type [C9H6-(CH2)(n)-O-Ar](2)ZrCl2 (n = 3-5; Ar = Ph, t-Bu-Ph) were synthesized, characterized, activated with methylalumoxane (MAO) and tested for ethylene polymerization. Structure-property-relationship studies showed that the activities of the catalysts depend on the length of the bridging chain between the indenyl and the phenoxy group as well as on the bulk at the phenoxy substituent. A t-Bu substituent at the ortho position of the phenoxy group (5a/MAO) gives a much higher catalyst activity (27,500 kg PE/mol cat h) than the isomer 8a/MAO with a t-Bu substituent at the para position of the phenoxy group (16,700 kg PE/mol cat h). Obviously substituents in the ortho position of the phenyl ring generate a bulkier catalyst cation and this can keep the MAO anion at a further distance to allow easier ethylene coordination and chain growth in the polymerization steps. The mono substituted bis(indenyl) complex (C9H7)[C9H6-(CH2)(4)-O-4-t-Bu]ZrCl2 shows lower activity (11,700 kg PE/mol cat h) than 8a indicating that the electronic effect is dominating in this type of catalysts. (C) 2015 Published by Elsevier B.V.

  DOI：

  10.1016/j.ica.2015.04.035
• 作为产物：
  描述：

  1,5-二溴戊烷 、 4-叔丁基苯酚 在 sodium n-propoxide 作用下， 以 丙醇 为溶剂， 反应 7.08h， 以74%的产率得到1-((5-bromopentyl)oxy)-4-(tert-butyl)benzene
  参考文献：
  名称：

  作为活性和选择性组胺H3受体配体的4-吡啶基-哌嗪衍生物的结构修饰和体外药理学评估。

  摘要：

  具有变化的烷基接头长度和东部取代基的一系列新的4-吡啶基哌嗪衍生物被证明是在纳摩尔浓度范围内有效的组胺H 3受体（hH 3 R）配体。在关注其烷基连接基长度的同时，具有六个亚甲基连接基的衍生物往往比其五个亚甲基同系物更有效。此外，就苯氧基乙酰基和苯氧基丙酰基衍生物而言，八个亚甲基连接基的活性均低于其七个亚甲基同系物。然而，在对烷基接头长度影响的收集数据的整体分析中，三个亚甲基同系物似乎是最高的hH 3。到目前为止，我们小组中所有已描述的4-吡啶基哌嗪衍生物之间的R亲和力。就联苯和二苯甲酮衍生物而言，具有对位取代的第二芳族环的化合物比其间类似物具有更高的亲和力。有趣的是，二苯甲酮衍生物18在所有测试的化合物中显示出最高的亲和力（hH 3 R K i  = 3.12 nM）。使用分子建模技术证明了造成其高亲和力的可能的蛋白质-配体相互作用。此外，使用体外方法评估了选择性，在H 3 R上的固有活性以及所选配体的类药物特性。

  DOI：

  10.1016/j.bioorg.2019.103071

文献信息

• Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors
  作者：Dorota Łażewska、Agnieszka Olejarz-Maciej、David Reiner、Maria Kaleta、Gniewomir Latacz、Małgorzata Zygmunt、Agata Doroz-Płonka、Tadeusz Karcz、Annika Frank、Holger Stark、Katarzyna Kieć-Kononowicz

  DOI：10.3390/ijms21103411

  日期：——

  based on the structure of 1-(3-(4-tert-butylphenoxy)propyl)piperidine (DL76). Probed modifications included the introduction of different cyclic amines and elongation of the alkyl chain. Synthesized compounds were investigated for human H3R (hH3R) affinity and human MAO B (hMAO B) inhibitory activity. Most compounds showed good hH3R affinities with Ki values below 400 nM, and some of them showed potent

  双靶配体是治疗帕金森氏病（PD）的有前途的概念。单胺氧化酶B（MAO B）抑制与组胺H3受体（H3R）拮抗作用的组合可能对多巴胺调节产生积极影响。因此，基于1-（3-（4-叔丁基苯氧基）丙基）哌啶（DL76）的结构，设计了一系列的二十七个4-叔丁基苯氧基烷氧基胺作为PD的潜在双靶配体。探索的修饰包括引入不同的环胺和延长烷基链。研究了合成的化合物对人H3R（hH3R）的亲和力和对人MAO B（hMAO B）的抑制活性。大多数化合物显示出良好的hH3R亲和力，Ki值低于400 nM，其中一些显示出对hMAO B的有效抑制活性，IC50值低于50 nM。然而，对两种生物学靶标的最平衡活性为DL76（hH3R：Ki = 38 nM和hMAO B：IC50 = 48 nM）。因此，选择了DL76进行进一步研究，揭示了DL76在HEK293和神经母细胞瘤SH-SY5Y细胞中的无毒性质。但是，在过氧化氢
• METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP0937703A1

  公开（公告）日：1999-08-25

  The present invention is directed to a method for purifying pyruvic acid compounds, which method comprises reacting a pyruvic acid compound of general formula (I): wherein R1 is an optionally substituted lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl group, an aryl group, or a heterocyclic group, and R2 is a lower alkyl group, with a bisulfite of general formula (II):         MHSO3     (II) wherein M is NH4 or an alkali metal, to give a bisulfite adduct of the pyruvic acid compound and then decomposing the adduct with an acid. According to the present invention, pyruvic acid compounds can be purified by simple and easy procedures without using purification techniques such as distillation or column chromatography, and the above method is advantageous as a process for the production on an industrial scale.

  本发明涉及一种纯化丙酮酸化合物的方法，该方法包括使通式(I)的丙酮酸化合物反应： 其中 R1 是任选取代的低级烷基、低级烯基、低级炔基、环烷基、芳基或杂环基，R2 是低级烷基，与通式（II）的亚硫酸氢盐反应： MHSO3 (II) 其中 M 为 NH4 或碱金属，以得到丙酮酸化合物的亚硫酸氢盐加合物，然后用酸分解该加合物。根据本发明，丙酮酸化合物可以通过简单易行的程序进行纯化，而无需使用蒸馏或柱层析等纯化技术，上述方法作为一种工业规模的生产工艺是非常有利的。
• Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof
  作者：Mikhail S. Novikov、Denis A. Babkov、Maria P. Paramonova、Anastasia L. Khandazhinskaya、Alexander A. Ozerov、Alexander O. Chizhov、Graciela Andrei、Robert Snoeck、Jan Balzarini、Katherine L. Seley-Radtke

  DOI：10.1016/j.bmc.2013.05.009

  日期：2013.7

  HCMV infection represents a life-threatening condition for immunocompromised patients and newborn infants and novel anti-HCMV agents are clearly needed. In this regard, a series of 1-[omega-(phenoxy)alkyl]uracil derivatives were synthesized and examined for antiviral properties. Compounds 17, 20, 24 and 28 were found to exhibit highly specific and promising inhibitory activity against HCMV replication in HEL cell cultures with EC50 values within 5.5-12 mu M range. Further studies should be undertaken to elucidate the mechanism of action of these compounds and the structure-activity relationship for the linker region. (C) 2013 Elsevier Ltd. All rights reserved.
• Novel aryloxyalkylthioimidazoles as inhibitors of acyl-CoA: cholesterol-O-acyltransferase
  作者：M Bani、R Bormetti、W Ceccarelli、R Fiocchi、M Gobetti、M Lombroso、S Magnetti、V Olgiati、M Palladino、M Villa、E Vanotti

  DOI：10.1016/0223-5234(96)88207-9

  日期：1995.1

  A series of aryloxyalkylthioimidazoles have been synthesized and evaluated for their ability,to interfere with the enzyme acyl-CoA (cholesterol-O-acyltransferase) (ACAT, EC 2.3.1.26). Most of the molecules possessed a good in vitro ACAT inhibitory activity with IC50 values ranging between 0.1 and 2.0 mu M Some of them, eg, 2-5-[(4-isobutoxycarbonyl)phenoxy]-pentylthio} -4,5-diphenylimidazole 13, 2-3-[(4-isobutoxycarbonyl)phenoxy]-2-oximinopropylthio}-4,5-diphenylimidazole 21, 2-3-[(4-isobutoxycarbonyl)phenoxy]-2-hydrazonecarboxamidepropylthio) -4,5-diphenylimidazole 26, 2-[5-(2-pyridoxy)-pentylthio]-4,5-diphenylimidazole 40 and 2-5-[(3,5-diterbutyl-4-hydroxy)phenylthio]pentylthio}-4,5-diphenylimidazole 42, were more potent (range of activity 10-90 nM). They were also more potent with respect to the reference CI-976. When administered orally in hyperlipemic rats, at 10 and 50 mg/kg doses, some representative compounds, like 2-3-[(4-isobutoxycarbonyl)phenoxy]-2-hydroxypropylthio}-4,5-diphenylimidazole 1, 13 and 26, reduced VLDL/LDL-associated cholesterol levels by 30-50% and increased HDL cholesterol levels by 15-50%. In addition, liver accumulation of esterified cholesterol was counteracted (50-80% reduction) and liver ACAT ex vivo activity was decreased by 70-85%. Finally, the good efficacy displayed in an endogenous model of hypertriglyceridemia strongly supports the hypothesis of a good systemic availability, which constitutes one of the principal properties of a valuable ACAT inhibitor.
• US6348617B1
  申请人：——

  公开号：US6348617B1

  公开（公告）日：2002-02-19